Risk of depression with GLP-1 receptor agonists use in overweight or obese adults with type 2 diabetes: A new-user, active-comparator cohort study.

ABSTRACT:

Aims

The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and depression remains uncertain due to contradictory evidence. We compared the risk of incident depression between GLP-1 RAs and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in overweight or obese adults with type 2 diabetes.

Materials and methods

We conducted a new-user, active-comparator cohort study using a deidentified electronic health record network from January 2016 to July 2024. After 1:1 propensity score matching, we compared 25 704 new GLP-1 RA users to 25 704 SGLT2i users with newly diagnosed type 2 diabetes and overweight/obesity, excluding those with prior mood disorders. The primary outcome was a composite of incident depression diagnosis or antidepressant initiation, ass

SUBMITTER: Chang Y 

PROVIDER: S-EPMC12673450 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature